Plasma-only ctDNA-Guided MRD Detection in Patients with CRC-Response

被引：3
|
作者：
Parikh, Aparna R. [1 ,2 ]
Corcoran, Ryan B. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Oncol, Dept Med, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
来源：
CLINICAL CANCER RESEARCH | 2021年 / 27卷 / 23期
关键词：
D O I：
10.1158/1078-0432.CCR-21-3306
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6614 / 6615
页数：2
相关论文
共 50 条
  • [31] Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
    Nagata, J.
    Nakamura, Y.
    Watanabe, J.
    Akazawa, N.
    Ikeda, M.
    Yokota, M.
    Kato, K.
    Kotaka, M.
    Yamazaki, K.
    Kagawa, Y.
    Yeh, K-H.
    Laliotis, G.
    Jurdi, A.
    Kotani, D.
    Bando, H.
    Taniguchi, H.
    Takemasa, I.
    Kato, T.
    Yoshino, T.
    Oki, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S457 - S457
  • [32] Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
    Xu, Yuyan
    Cai, Jianpeng
    Zhong, Kaihang
    Wen, Yaohong
    Cai, Lei
    He, Guolin
    Liao, Hangyu
    Zhang, Cheng
    Fu, Shunjun
    Chen, Tingting
    Cai, Jinping
    Zhong, Xuefeng
    Chen, Chunzhu
    Huang, Mengli
    Cheng, Yuan
    Pan, Mingxin
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression
    Edmund Lau
    Patrick McCoy
    Fairleigh Reeves
    Ken Chow
    Michael Clarkson
    Edmond M. Kwan
    Kate Packwood
    Helen Northen
    Miao He
    Zoya Kingsbury
    Stefano Mangiola
    Michael Kerger
    Marc A. Furrer
    Helen Crowe
    Anthony J. Costello
    David J. McBride
    Mark T. Ross
    Bernard Pope
    Christopher M. Hovens
    Niall M. Corcoran
    Genome Medicine, 12
  • [34] Detection of EGFR mutations in ctDNA in plasma samples of NSCLC patients by two simultaneously applied methods
    Farkasova, A.
    Scheerova, K.
    Plank, L.
    VIRCHOWS ARCHIV, 2019, 475 : S54 - S54
  • [35] Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression
    Gabriela Marsavela
    Ashleigh C. McEvoy
    Michelle R. Pereira
    Anna L. Reid
    Zeyad Al-Ogaili
    Lydia Warburton
    Muhammad A. Khattak
    Afaf Abed
    Tarek M. Meniawy
    Michael Millward
    Melanie R. Ziman
    Leslie Calapre
    Elin S. Gray
    British Journal of Cancer, 2022, 126 : 401 - 408
  • [36] Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression
    Marsavela, Gabriela
    McEvoy, Ashleigh C.
    Pereira, Michelle R.
    Reid, Anna L.
    Al-Ogaili, Zeyad
    Warburton, Lydia
    Khattak, Muhammad A.
    Abed, Afaf
    Meniawy, Tarek M.
    Millward, Michael
    Ziman, Melanie R.
    Calapre, Leslie
    Gray, Elin S.
    BRITISH JOURNAL OF CANCER, 2022, 126 (03) : 401 - 408
  • [37] Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression
    Lau, Edmund
    McCoy, Patrick
    Reeves, Fairleigh
    Chow, Ken
    Clarkson, Michael
    Kwan, Edmond M.
    Packwood, Kate
    Northen, Helen
    He, Miao
    Kingsbury, Zoya
    Mangiola, Stefano
    Kerger, Michael
    Furrer, Marc A.
    Crowe, Helen
    Costello, Anthony J.
    McBride, David J.
    Ross, Mark T.
    Pope, Bernard
    Hovens, Christopher M.
    Corcoran, Niall M.
    GENOME MEDICINE, 2020, 12 (01)
  • [38] Detection of minimal residual disease (MRD) in colorectal cancer (CRC) patients UICC stage II/III by ultra-deep sequencing of cfDNA from post-surgery plasma
    McNamara, Sylvie
    Patel, Rajesh D.
    Adams, Hans-Peter
    Qu, Xueping
    Hinzmann, Bernd
    Wong, Cheryl V.
    Heilek, Gabrielle
    Mantke, Rene
    Heise, Michael
    Steinmueller, Thomas
    Pross, Matthias
    Marusch, Frank
    Bais, Carlos
    Palma, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.
    Shah, Purvi K.
    Aushev, Vasily N.
    Ensor, Joe
    Sanchez, Stephanie A.
    Wang, Christopher Gene
    Cannon, Timothy Lewis
    Berim, Lyudmyla Derby
    Feinstein, Trevor
    Grothey, Axel
    McCollom, Joseph William
    Kalmadi, Sujith R.
    Zakari, Ahmed
    Dayyani, Farshid
    Gravenor, Don
    Liu, Minetta C.
    Jurdi, Adham A.
    Aleshin, Alexey
    Meyer, Janelle Marie
    Sharif, Saima
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 15 - 15
  • [40] Genomic alterations in circulating tumor DNA (ctDNA) and response to telisotuzumab adizutecan (ABBV-400) treatment in patients (pts) with colorectal cancer (CRC).
    Cecchini, Michael
    Sharma, Manish R.
    Kuboki, Yasutoshi
    Perets, Ruth
    Cohen, Jonathan
    Raimbourg, Judith
    Nakajima, Takako Eguchi
    Cruz-Correa, Marcia
    Ghiringhelli, Francois
    Raghav, Kanwal Pratap Singh
    Vasilopoulos, Athanasios
    Luo, Xizhi
    Aristide, Martha Raluca Neagu
    Thiele, Gladys Morrison
    Hunter, Zoe
    Burns, Michael Charles
    Roberts-Rapp, Lisa
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 258 - 258
12345